Category: Infectious Diseases
Poster Session I
Evaluate the mother-to-infant transmission of SARS-CoV-2 and antibody transfer patterns following prenatal infection.
Study Design: Prospective cohort study of pregnant individuals in Ontario, Canada with COVID-19 in pregnancy. Sample collection at delivery included maternal swabs (nasopharyngeal/oropharyngeal, vaginal, anorectal), blood, breastmilk, newborn swab (nasopharyngeal, sub-amniotic), amniotic fluid, cord blood and placenta. Samples were analyzed by qPCR for SARS-CoV-2 RNA and IgG assays targeting the SARS-CoV-2 spike (S), nucleocapsid (N) and receptor binding domain (RBD) proteins. Placentas were evaluated for frequency and type of histologic lesions.
Results: The cohort included 213 individuals diagnosed with SARS-CoV-2 infection during pregnancy between Mar-2020 and Aug-2021, and their 215 exposed newborns. Median gestational age at COVID-19 diagnosis was 30.1 weeks (IQR 14.4). Most infections were mild (70.4%) and symptomatic (77.5%). A total 64/144 (44.8%) participants had active SARS-CoV-2 infections at delivery, as did 21/142 (14.8%) newborns. SARS-CoV-2 was also evident in vaginal (3/182), anorectal (5/175), sub-amniotic (1/165), breastmilk (1/38) and amniotic fluid (3/77) samples. A total of 118/193 (61.1%) maternal and 138/189 (73%) cord serum samples were positive for IgG COVID-19 antibodies. Maternal and cord serum anti-RBD, anti-N and anti-S IgG were significantly and positively correlated (R=0.26, 0.24, 0.23, respectively; p< 0.05 for all). The antibody transfer ratio of anti-RBD was significantly correlated with the number of weeks since maternal infection during pregnancy (R=0.28, p< 0.05). SARS-CoV-2 was detected in 6/138 (4.3%) placentas; placentas were characterized by acute (33/113) and chronic inflammation (20/113), and maternal (39/113) and fetal (12/113) vascular malperfusion.
Conclusion:
In this cohort, the rate of SARS-CoV-2 vertical transmission and transfer of maternal antibodies to newborn was high. Further investigation into the circumstances in which vertical transmission of SARS-CoV-2 occurs and its implication on maternal-fetal antibody transfer is needed.
Darine El-Chaar, MD, MSc (she/her/hers)
Associate Scientist
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Malia Murphy, PhD
Senior Clinical Research Associate
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Alysha Dingwall-Harvey, MSc
Program Manager
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Sheryll Dimanlig-Cruz, MSc
BORN Ontario
Ottawa, Ontario, Canada
Stephanie Boyd, MBA, MSc
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Serine Ramlawi, MSc
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Romina Fakhraei, MSc
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Ruth Rennicks-White, RN
Program Manager
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Daniel Corsi, MSc, PhD
Scientist
Children's Hospital of Eastern Ontario Research Institute
Ottawa, Ontario, Canada
Katherine Muldoon, PhD
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Barbra De Vrijer, MD
London Health Sciences Centre
London, Ontario, Canada
Elad Mei-Dan, MD
University of Toronto
Toronto, Ontario, Canada
Sarah Lawrence, MD
Children’s Hospital of Eastern Ontario
Ottawa, Ontario, Canada
Jason Brophy, MD, MSc
Children’s Hospital of Eastern Ontario
Ottawa, Ontario, Canada
Deshayne Fell, PhD
University of Ottawa
Ottawa, Ontario, Canada
Mark Walker, MD, MHA, MSc
Senior Scientist
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Marc-André Langlois, PhD
University of Ottawa
Ottawa, Ontario, Canada